Today: 1 July 2026
Browse Category

NASDAQ:PGSUS 27 December 2025

Pegasus Resumes Istanbul–Sulaymaniyah Flights as Turkey Lifts Airspace Ban, Giving Sabiha Gökçen a Year-End Route Boost

Pegasus Resumes Istanbul–Sulaymaniyah Flights as Turkey Lifts Airspace Ban, Giving Sabiha Gökçen a Year-End Route Boost

Pegasus Airlines has restarted direct flights between Istanbul and Sulaymaniyah in Iraq’s Kurdistan Region, restoring a key air link that had been disrupted for more than two years and giving Istanbul Sabiha Gökçen International Airport what local aviation outlets are calling its “last route opening of the year.” Kurdistan24 - کوردستان 24+2HavaSosyalMedya+2 The resumption is more than a new line on a departure board. It comes after Türkiye lifted restrictions affecting Sulaymaniyah International Airport, a move that has triggered the return of multiple Turkish carriers and raised expectations of renewed business, family, and tourism travel between Istanbul and the Kurdistan Region. Kurdistan24 - کوردستان 24+1
27 December 2025

Stock Market Today

  • Kymera Therapeutics (KYMR) up 51% YTD as atopic dermatitis drug hits milestones
    July 1, 2026, 2:57 PM EDT. Kymera Therapeutics (KYMR) is up nearly 51% this year, way ahead of the sector's 6.4%. The stock's gain is tied to progress on KT-621, an oral STAT6 degrader for atopic dermatitis and asthma. Kymera wrapped phase IIb enrollment in the BROADEN2 AD trial six months early, aiming to have the pivotal readout by late 2026. Earlier, phase Ib data showed strong STAT6 knockdown and safety. The FDA put KT-621 on Fast Track for moderate-to-severe AD and eosinophilic asthma. Separately, trials for KT-485, in partnership with Sanofi, led to a $20 million milestone, and Kymera is still developing KT-579. Its alliances with Sanofi and Gilead are part of the company's long-term plans.
Go toTop